Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Antiviral Res. 2012 Feb 15;94(1):1–8. doi: 10.1016/j.antiviral.2012.02.001

Table 1.

Oligonucleotide primers for amplification and modification of antibody V-regions

Primer Name Sequencea
First Round Primers
M-IgG2a 5′ ATTCGGATAGATCTAGTGGATAGACCGATGG 3′
MK-REV 5′ ATTCGGATAGATCTTGGATGGTGGGAAGATG 3′
MHV-5 5′ ACTAGTCGACATGGACTCCAGGCTCAAT TTAGTTTTCCTT 3′
MKV-4 5′ ACTAGTCGACATGAGGGCCCCTGCTCACTTTTTTGGCTTCTTG 3′
Second Round Primers
VK-5′ 5′ TCACGAAGTCTAGACTGGACATGAGGGCCCCTGCTCACTTTTTTGG 3′
VK-3′ 5′ GAATCTATGGATCCTGACACACTTACGCTTTATTTCCAACTTTGTCCCCGA 3′
VH-5′ 5′ ACACTATACTCGAGCTCACGATGAACTTTGGGCTCAGCTTGATTT 3′
VH-3′ 5′ TTCAGATCAAGCTTGACACACTTACCTGAGGAGACGGTGACTGAGGTTC 3′
a

Restriction endonuclease sites are underlined

HHS Vulnerability Disclosure